1. Lithium Argentina (NYSE:LAR)

Year-to-date gain: 106.39 percent
Market cap: US$891.03 million
Share price: US$5.49

Lithium Argentina produces lithium carbonate from its Caucharí-Olaroz brine project in Argentina, developed with Ganfeng Lithium (OTC Pink:GNENF,HKEX:1772). The company was spun out from Lithium Americas in October 2023 and changed its name from Lithium Americas (Argentina) in January 2025.

In mid-April, Lithium Argentina executed a letter of intent with Ganfeng Lithium to jointly advance development across the Pozuelos-Pastos Grandes basins.

In August, Lithium Argentina agreed to form a new joint venture with Ganfeng Lithium that will combine the companies’ projects in the Pozuelos and Pastos Grandes basins of Salta, Argentina.

The joint venture will bring together Ganfeng’s wholly owned Pozuelos-Pastos Grandes (PPG) project and Lithium America’s Pastos Grandes and Sal de la Puna projects, in which Ganfeng currently holds a 15 percent and 35 percent stake respectively.

Once completed, Ganfeng will hold a 67 percent stake in the consolidated PPG project, and Lithium Argentina will hold a 33 percent interest.

In Q4, Lithium Argentina released a positive scoping study for the PPG project, confirming its scale and strong economics. The consolidated project hosts a measured and indicated resource of 15.1 million metric tons of lithium carbonate equivalent (LCE) and is designed for staged production of up to 150,000 metric tons per year over a 30 year mine life.

In the same announcement, the company confirmed receipt of an environmental approval for Stage 1 from the Secretariat of Mining and Energy of the Province of Salta.

Lithium Argentina released its Q3 results in November, noting approximately 8,300 metric tons of lithium carbonate production at its Caucharí-Olaroz operation during the quarter, with 24,000 metric tons produced between January and September.

Company shares rose to a year-to-date high of US$5.58 on December 31, in line with rising lithium carbonate prices.

2. Sociedad Química y Minera (NYSE:SQM)

Year-to-date gain: 87.39 percent
Market cap: US$19.66 billion
Share price: US$68.98

SQM is a major global lithium producer, with operations centered in Chile’s Salar de Atacama. The company extracts lithium from brine and produces lithium carbonate and hydroxide for use in batteries.

SQM is expanding production and holds interests in projects in Australia and China, including a 50/50 joint venture for the Mt Holland lithium operation in Western Australia. In July, the company produced its first battery-grade lithium hydroxide production at its Kwinana refinery in the state.

In late April, Chile’s competition watchdog approved the partnership agreement between SQM and state-owned copper giant Codelco aimed at boosting output at the Atacama salt flat. The deal, first announced in 2024, reached another milestone when it secured approval for an additional lithium quota from Chile’s nuclear energy regulator CChEN.

SQM ended the year finalizing the agreement. The partnership was formalized through SQM’s subsidiary SQM Salar absorbing Codelco’s Minera Tarar and being renamed Nova Andino Litio.

SQM reported a net income of US$404.4 million for the first nine months of 2025, rebounding from a US$524.5 million loss in the same period of 2024. Revenue totaled US$3.25 billion, down 5.9 percent year-over-year, while gross profit reached US$904.1 million.

The company’s third-quarter performance highlighted the turnaround, as SQM achieved record lithium sales volumes. It reported net income of US$178.4 million, up 36 percent from Q3 2024, and revenue of US$1.17 billion, up 8.9 percent. Gross profit for the quarter climbed 23 percent to US$345.8 million.

SQM attributed the rebound to higher realized lithium prices and improved operational efficiency, signaling a strong recovery trajectory for the remainder of 2025.

Shares of SQM reached a year-to-date high of US$71.63 on December 26.

3. Albemarle (NYSE:ALB)

Year-to-date gain: 64.29 percent
Market cap: US$16.71 billion
Share price: US$142.01

North Carolina-based Albemarle is dividing into two primary business units, one of which — the Albemarle Energy Storage unit — is focused wholly on the lithium-ion battery and energy transition markets. It includes the firm’s lithium carbonate, hydroxide and metal production.

Albemarle has a broad portfolio of lithium mines and facilities, with extraction in Chile, Australia and the US. Looking first at Chile, Albemarle produces lithium carbonate at its La Negra lithium conversion plants, which process brine from the Salar de Atacama, the country’s largest salt flat. Albemarle is aiming to implement direct lithium extraction technology at the salt flat to reduce water usage.

Albemarle’s Australian assets Wodgina hard-rock lithium mine in Western Australia, which is owned and operated by the 50/50 MARBL joint venture with Mineral Resources (ASX:MIN,OTC Pink:MALRF). Albemarle wholly owns the on-site Kemerton lithium hydroxide facility. The company’s other Australian joint venture is the Greenbushes hard-rock mine, in which it holds a 49 percent interest.

In late October, Albemarle signed an agreement to sell its 51 percent stake in its refining catalyst business, Ketjen, leaving it with 49 percent ownership, part of a broader portfolio reshaping that also includes the sale of Ketjen’s 50 percent stake in the Eurecat joint venture to partner Axens.

The combined deals are expected to generate approximately US$660 million in pre-tax cash proceeds and strengthen Albemarle’s financial flexibility. Both transactions are anticipated to close in the first half of 2026, subject to regulatory approvals.

In November, Albemarle reported third‑quarter results that reflected improved operations amid continued lithium market headwinds. The company logged net sales of roughly US$1.31 billion, a slight year‑over‑year decline driven by lower energy storage pricing.

Albemarle generated US$356 million in quarterly cash from operations, noting the company remained on track to reduce full‑year capital expenditures to around US$600 million while targeting positive free cash flow of US$300 million to US$400 million in 2025.

Shares of Albemarle marked a year-to-date high of US$150.01 on December 26, amid strengthening lithium prices.

4. Lithium Americas (NYSE:LAC)

Year-to-date gain: 47 percent
Market cap: US$1.24 billion
Share price: US$4.41

US-focused Lithium Americas is developing its flagship Thacker lithium Pass project located in Humboldt County in northern Nevada. The project is a joint venture between Lithium Americas at 62 percent and General Motors (NYSE:GM) at 38 percent.

According to the company, Thacker Pass holds the “largest measured lithium reserve and resource in the world.”

In March, Lithium Americas secured a US$250 million investment from Orion Resource Partners to advance Phase 1 construction of the project, which is expected to fully cover development costs through the construction phase. On April 1, the joint venture partners made a final investment decision for the project, with completion targeted for late 2027.

Shares of Lithium Americas surged in late September, rising from US$3.07 to US$7.37 in three days. Its share price reached a 2025 high of US$10.05 on October 13.

Lithium Americas’ share price rose on news of renegotiation talks over its US$2.26 billion Department of Energy loan tied to the Thacker Pass project. According to media reports, the Trump administration was seeking up to a 10 percent equity stake as part of amendments to the loan’s repayment structure.

In response, Lithium Americas offered no-cost warrants for 5 to 10 percent of its shares and agreed to cover related administrative costs, while requesting changes to the amortization schedule without altering the loan’s term or interest.

An agreement was reached on October 1 and Lithium Americas received the first US$435 million installment of the loan on October 20.

The company ended the year by announcing it was being added to the S&P/TSX Composite Index (INDEXTSI:OSPTX).

5. Sigma Lithium (NASDAQ:SGML)

Year-to-date gain: 20.23 percent
Market cap: US$1.5 billion
Share price: US$13.49

Sigma Lithium is a Brazil-focused lithium producer supplying chemical-grade lithium concentrate to the global battery market. The company operates the Grota do Cirilo project in Minas Gerais, one of the world’s largest hard-rock lithium operations.

Sigma’s Greentech industrial lithium plant currently produces about 270,000 metric tons per year of lithium concentrate, equivalent to roughly 38,000 to 40,000 metric tons of LCE. The company is building a second processing plant that is expected to lift total capacity to approximately 520,000 metric tons of concentrate annually.

In September, Sigma Lithium’s flagship Grota do Cirilo operation in Brazil faced both regulatory scrutiny and operational disruption.

That month, Brazilian prosecutors requested a pause in operations after a technical review flagged shortcomings in the project’s Environmental Impact Assessment, citing potential water-management risks to the Piauí stream from planned open pits, a key water source for nearby communities, particularly during droughts.

While it denied issues with its EIA, Sigma paused mining to upgrade equipment and improve efficiency. The company phased down operations in September and shut the mine throughout October, leading to a sharp drop in output.

In mid-November, Sigma reported a strong Q3 2025, with net revenue rising 69 percent quarter-over-quarter and 36 percent year-over-year. The company generated US$24 million from final price settlements on sales completed by the end of Q3, with a further US$4 million in cash expected from additional settlements.

Sigma also expects to receive approximately US$33 million from the sale of 950,000 metric tons of lithium-bearing material that can be reprocessed by its customers, providing an additional near-term cash inflow.

Operationally, it said mining activities would restart by the end of November, with full ramp-up targeted for the first quarter of 2026. Because the company took over mining operations from its equipment contractor earlier in 2025, the restart is supported by upgraded equipment leased directly from manufacturers and operated in-house.

Sigma Lithium shares rose to a year-to-date high of US$14.50 on December 26.

Copper outlook for 2026

Market watchers expect many of the forces that drove copper through 2025 to persist.

Supply constraints are expected to remain acute this year as aging mines and capacity shortfalls weigh on availability. New projects such as Arizona Sonoran Copper Company’s (TSX:ASCU,OTCQX:ASCUF) Cactus project and the long‑anticipated Resolution mine in the US are still years from significant output.

Copper demand is projected to grow as the global energy transition accelerates.

“A huge amount of this tightness has to do with US tariff concerns,” she said.

China, the world’s largest copper consumer, is also shaping the outlook. Despite weakness in its property sector, the country posted economic growth and is expected to prioritize copper‑intensive sectors under its new five year plan.

Longer‑term projections from industry groups suggest structural demand growth will outpace supply additions.

A UN report estimates that copper demand could rise 40 percent by 2040, requiring substantial investment and new mines just to keep pace. Likewise, Wood Mackenzie forecasts that copper demand will increase 24 percent by 2035, while the International Copper Study Group predicts a refined copper deficit of 150,000 metric tons in 2026 alone.

European cannabis legalization and international growth

2025 brought incremental legalization or medical frameworks in multiple jurisdictions, including Czechia, Malta, Poland, Switzerland and Luxembourg, broadening the investable global footprint.

This continental momentum has directly boosted North American producers through export ramps and licensing deals, with Canadian licensed producers capturing 43 percent of Germany’s Q2 imports alone.

The country’s CanG framework and adult‑use reform, which came into effect in April 2024, have made it Europe’s most important legal market, with 2025 medical sales expected to see explosive year-on-year growth.

Investor takeaway

2025 marked a transformative year for cannabis, with regulatory breakthroughs and market maturation set against the backdrop of volatility. Trump’s execuctive order has brought new life into the sector in the US with the promise of not only banking and tax relief, but also bipartisan momentum for normalization; however, investors remain cautious.

“Everybody is waiting for it to be real and for it to be completed. Because even though we think the executive order was huge … nothing’s complete yet. Nothing’s official yet,” explained Ahrens.

Looking to 2026, he emphasized that the path forward for cannabis isn’t a straight line, but rather a series of volatile ‘waves’ tied to incremental regulatory milestones. Ahrens anticipates that while the finalization of Schedule III should trigger an initial move, it is merely the first domino; subsequent upside depends on the DoJ providing clear guidance for state-legal adult-use programs and the eventual passage of banking reform.

While he does foresee cannabis stocks uplisting to major exchanges, and Big Pharma companies beginning to make acquisitions in the space, Ahrens remains cautious about timing, noting that even with a signed order, large institutional banks will likely keep the ‘blockade’ in place until the legal ink is truly dry.

Ultimately, while 2025’s executive action has established a concrete foundation for federal reform in the US, the cannabis sector remains poised in a state of high-stakes volatility, with its full maturation dependent on official completion of milestones in 2026 and beyond.

1. MDxHealth (NASDAQ:MDXH)

Year-on-year gain: 50.86 percent
Market cap: US$173.24 million
Share price: US$3.50

MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.

The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms.

In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026.

2. KORU Medical Systems (NASDAQ:KRMD)

Year-on-year gain: 50.13 percent
Market cap: US$269.6 million
Share price: US$5.82

KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.

Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.

KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo — a HER2+ breast cancer targeted biologic — subcutaneously, targeting infusion centers to cut chair time and boost efficiency.

The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.

3. Vivani Medical (NASDAQ:VANI)

Year-on-year gain: 1.71 percent
Market cap: US$86.81 million
Share price: US$1.19

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.

Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.

In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects.

The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026.

Investor Insight

Centurion Minerals offers investors an early-stage entry point into a strategically located gold exploration company positioned within one of North America’s most prolific and active mining districts. With a restructured corporate foundation, and a highly experienced geological and corporate finance team, the company is primed for value-creating discoveries.

Overview

Centurion Minerals (TSXV:CTN) is a Canadian exploration company focused on the acquisition, exploration and development of precious metals projects in the Americas.

The company’s strategy is centered on advancing high-quality, early-stage gold assets through systematic exploration to define drill-ready targets and unlock the discovery potential inherent in its three-part claim package: the Newman, Noseworthy and Hepburn properties. Situated near major operations and new discoveries, these claims benefit from excellent infrastructure, year-round road access and proximity to proven mineralized structural corridors. Centurion intends to increase shareholder value through targeted geophysics, ground truthing and drilling programs designed to reveal new high-grade zones, as well as through potential future acquisitions of complementary gold assets across the Americas.

Backed by a leadership team with decades of exploration, geology, corporate finance and project development experience, Centurion is positioned to capitalize on strong gold market fundamentals and renewed investor interest in junior exploration companies. With a low current valuation and advancing work program, the company provides leverage to both exploration success and broader trends in the gold sector.

Company Highlights

• Highly prospective gold project in a world-class district located in the central north Abitibi greenstone belt, adjacent to major deposits and producing mines including Hecla Mining’s (NYSE:HL) Casa Berardi mine and Agnico Eagle’s (TSX:AEM) Detour Lake operations.
• Exceptional closeology advantage, with its Casa Berardi West project situated just 12 km from AMEX Exploration’s (TSXV:AMX) 1.6 Moz “Perron” discovery and along the same structural corridors that have produced multi-million-ounce deposits.
• Significant historic drilling across the three claim groups, including results up to 38 g/t gold and multiple intervals indicating gold-bearing iron formations and shear zones.
• Clear exploration strategy including historic data compilation, geophysical surveys, target generation and a planned program to define new mineralized zones.
• Experienced management and technical team with decades of experience in mineral exploration, and international corporate finance, enhances the potential of uncovering additional exploration opportunities.
• Low market capitalization and recently reactivated corporate structure, offering investors a low entry point ahead of meaningful upside catalysts.

Key Project

Casa Berardi West Gold Project

The Casa Berardi West project is Centurion’s flagship gold exploration asset, encompassing approximately 6,732 hectares across three contiguous claim groups – Newman, Noseworthy and Hepburn – located 66 km northeast of Cochrane, Ontario. The project sits along structural corridors that host some of the region’s most significant deposits, including Hecla Mining’s Casa Berardi mine (3 Moz past production, plus 4 Moz in reserves and resources), Agnico Eagle’s Detour Lake mine (15 Moz reserve, producing ~659,000 oz of gold per year ), and AMEX Exploration’s Perron discovery (1.6 Moz measured and indicated resource at 6.14 g/t gold).

Location of the three claim groups at Casa Berardi West

Geological Setting & Closeology Advantage

The project is situated within the central north Abitibi Subprovince, an Archean greenstone belt known globally for its prolific endowment of gold and base metals. The claims lie adjacent to geological features associated with multiple major deposits – iron formations, shear zones and VMS trends – creating strong analogues to high-grade gold mines such as the Musselwhite mine in Northern Ontario.

This “closeology” positioning significantly enhances the potential for Centurion’s ground to host similar mineralization.

Historic Results & Target Areas

Historic exploration across the Casa Berardi West project – spanning more than 70 RC and diamond drill holes – has already confirmed the presence of gold-bearing structures and favorable host rocks. Notably, previous work returned multiple samples above 1 g/t gold, including a standout result of 38 g/t gold, demonstrating strong mineralization potential across the claim area.

Significant historic drill results at Newman target

Across the three claim groups, drilling and geophysical surveys have identified key geological features associated with major deposits in the region, including iron formations, shear zones and sulphidized horizons. Several zones of interest remain untested or underexplored, particularly along structural trends that extend from nearby high-grade gold and VMS systems such as the Perron and Normetal areas.

These findings provide Centurion with multiple high-priority target areas for follow-up exploration, forming the foundation for its next phase of geophysical work and upcoming drill targeting.

Management Team

David Tafel – Director, President and CEO

David Tafel brings over 30 years of experience in corporate structuring, strategic planning, financing and executive management across multiple public and private resource companies. He has raised several hundred million dollars for ventures in mining, technology and life sciences, and previously managed private investment funds at Canada’s largest independent securities firm.

Jeremy Wright – Director and CFO

A seasoned financial executive with more than 20 years of experience, Jeremy Wright serves as president & CEO of Seatrend Strategy Group and has held CFO roles across numerous public companies in the resource and technology sectors. His background includes financial management, negotiations and environmental economics, supported by extensive board leadership experience.

Joseph Del Campo – Director

Joseph Del Campo has served as CFO and Interim CEO across several mining companies, including Unigold and First Nickel. With decades of corporate financial leadership and board experience, he contributes deep governance, audit and operational oversight expertise to Centurion’s board.

Mike Kilbourne – Geological Consultant

A veteran geologist with 40+ years of industry experience, Mike Kilbourne has managed over 100,000 metres of drilling across North America and Mexico, worked as a production geologist in multiple mining environments, and generated over 700 exploration targets for private and public companies.

Jamie Lavigne – Geological Consultant

Jamie Lavigne is a senior exploration geologist with more than 30 years of experience in base and precious metals. He has held senior technical roles with major mining companies and specializes in advanced exploration, resource delineation and geological modeling across global mineral belts.

1. HLS Therapeutics (TSX:HLS)

Year-on-year gain: 26.6 percent
Market cap: C$149.8 million
Share price: C$4.76

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia.

HLS in-licensed the exclusive rights to the treatments Nilemdo and Nexlizet, both of which are already approved in other countries, from Esperion (NASDAQ:ESPR) in May.

The November 2025 Health Canada approval of LDL-cholesterol lowering treatment Nilemdo represents the most significant catalyst for the company since the launch of Vascepa, positioning HLS as a dominant leader in the Canadian cardiovascular market. The company is targeting Nilemdo’s commercial launch in Q2 2026.

Along with the approval, Health Canada issued a notice of non-compliance for its Nexlizet cholesterol-reducing treatment. According to HLS, the decision was related to chemistry, manufacture and controls data, not clinical data or safety.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

2. Satellos Bioscience (TSXV:MSCL)

Year-on-year gain: 14.49 percent
Market cap: C$141.04 million
Share price: C$0.79

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue.

Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

In Q4 2025, Satellos administered the first dose to a patient in its 11-month open-label follow-up study for adults who completed its initial Phase 1b trial. The study seeks to demonstrate the lasting impact of the significant functional improvements observed earlier in the year.

On December 9, the company received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.

3. Knight Therapeutics (TSX:GUD)

Year-on-year gain: 14.29 percent
Market cap: C$592.59 million
Share price: C$6.00

Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Québec. It operates on an acquisition and in-licensing model, obtaining the rights to innovative medicines from global pharmaceutical companies and commercializing them across Canada and Latin America.

The company was originally founded by the former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought the Paladin business back from Endo for C$107 million, adding over 40 products to Knight’s Canadian roster.

The additions, helped drive 32 percent revenue growth year-over-year to a record C$122.55 million in Q3. The company projects its Knight Canada subsidiary will be the company’s top revenue-contributor within two years.

4. BioSyent (TSXV:RX)

Year-on-year gain: 10.07 percent
Market cap: C$146.89 million
Share price: C$12.90

BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring established, high-margin healthcare products for the Canadian and international markets. Its growth is anchored by brands in iron health and women’s wellness. Its flagship brand, FeraMAX, has been Canada’s leading iron supplement for over a decade.

The company’s 2024 acquisition of Tibella, a treatment for menopausal symptoms, has been a major growth driver. According to its Q3 earnings report. BioSyent’s sales grew 19 percent year-over-year in Canada and 94 percent in the international market.

5. NurExone Biologic (TSXV:NRX)

Year-on-year gain: 6.45 percent
Market cap: C$47.54 million
Share price: C$0.66

NurExone Biologic is behind ExoTherapy, a drug-delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US FDA in October 2023.

The company expects to initiate its Phase 1/2a first-in-human trial for acute spinal cord injury in the second half of 2026, targeting patients with traumatic injuries.

It continues to make significant progress, with recent preclinical studies demonstrating strong, dose-dependent vision recovery in glaucoma models and improved motor function in spinal cord injury models.

The company announced plans for a US exosome production facility in Indianapolis, Indiana, in September. According to the release, ‘The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.’

In December, the company began planning for small-scale production of ExoPTEN in Israel to support its clinical trial.